PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  04:04 2022-08-12 pm EDT
50.11 USD   +3.77%
08/12Creighton students' COVID vaccine mandate appeal dismissed
AQ
08/12Drugmakers' shares up after Zantac lawsuit slump
RE
08/12Biotech stocks pin bounce back hopes on M&A boost
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer Inc. and BioNTech SE Announces New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine

06/29/2022 | 04:45pm EDT

Pfizer Inc. and BioNTech SE announced a new vaccine supply agreement with the U.S. government to support the continued fight against COVID-19. Under the agreement, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg). This may include adult Omicron-adapted COVID-19 vaccines, subject to authorization from the U.S. Food and Drug Administration (FDA). The doses are planned to be delivered as soon as late summer 2022 and continue into the fourth quarter of this year. The U.S. government will pay the companies $3.2 billion upon receipt of the first 105 million doses. Under this agreement, the U.S. government also has the option to purchase up to 195 million additional doses, bringing the total number of potential doses to 300 million.


© S&P Capital IQ 2022
All news about PFIZER, INC.
08/12Creighton students' COVID vaccine mandate appeal dismissed
AQ
08/12Drugmakers' shares up after Zantac lawsuit slump
RE
08/12Biotech stocks pin bounce back hopes on M&A boost
RE
08/12Oncolytics Biotech Reports Second Quarter 2022 Financial Results and Recent Operational..
AQ
08/12There are two ways to see inflation data
MS
08/12Pfizer Says Pneumococcal Disease Vaccine Has Potential to Provide Broadest Serotype Cov..
MT
08/12Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal..
BU
08/12GSK, Sanofi, Haleon Shares Recover Some Recent Losses After Zantac Drug Responses
DJ
08/12Haleon Says It Hasn't Been Notified About Litigation on Zantac Drug -- Update
DJ
08/12Haleon Says it Hasn't Been Notified About Litigation on Zantac Drug
DJ
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 102 B - -
Net income 2022 32 675 M - -
Net cash 2022 11 522 M - -
P/E ratio 2022 8,89x
Yield 2022 3,23%
Capitalization 281 B 281 B -
EV / Sales 2022 2,65x
EV / Sales 2023 3,37x
Nbr of Employees 79 000
Free-Float 59,0%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 50,11 $
Average target price 56,53 $
Spread / Average Target 12,8%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-15.14%281 235
JOHNSON & JOHNSON-3.37%434 603
ELI LILLY AND COMPANY11.53%292 730
ROCHE HOLDING AG-16.91%275 562
ABBVIE INC.5.32%252 131
NOVO NORDISK A/S4.76%240 550